Kidney Cancer Coverage from Every Angle
Advertisement
Advertisement

Recent News

CheckMate 920: Nivolumab Plus Ipilimumab for Renal Cell Carcinoma With Brain Metastases
Can Nephrectomy Prior to Immunotherapy Improve Survival in Renal Cell Carcinoma?
Lenvatinib Plus Pembrolizumab in Renal Cell Carcinoma: Phase IB/II Trial Results
Nivolumab Alone and in Combination Therapy for Non–Clear Cell Kidney Cancer
Lenvatinib/Everolimus in Advanced Kidney Cancer: Outcomes in a Real-World Setting
Do Patient Demographics Influence Treatment Decisions in Kidney Cancer?
New Use for Older Antifungal Agent: Adjunct to Therapy for Kidney Cancer?
ASCO 2021: Telaglenastat Plus Cabozantinib in Advanced Renal Cell Carcinoma
ASCO 2021: mTOR- and VEGF-Targeted Agents in Metastatic Renal Cell Carcinoma
ASCO 2021: Does Immunotherapy Improve Outcomes in Aggressive Subtype of Kidney Cancer?
ASCO 2021: Impact of Lenvatinib-Based Therapy on Quality of Life in Renal Cell Carcinoma
ASCO 2021: Can Live Bacterial Product Enhance Response to Immunotherapy in Metastatic Renal Cell Cancer?
Updated AUA Guidelines Focus on Renal Masses and Localized Renal Cancer
ASCO 2021: 42-Month Follow-up of Pembrolizumab Plus Axitinib in Advanced Clear Cell Kidney Cancer
ASCO 2021: KEYNOTE-564 Evaluates Pembrolizumab as Adjuvant Therapy After Nephrectomy
After Radical Nephrectomy: Risk Factors Associated With Locoregional Recurrence
Advanced Kidney Cancer in Arizona: Are Hispanic and Native Americans at Increased Risk of Mortality?
Brain Metastasis 15 Years After Radical Nephrectomy for Renal Cell Carcinoma: Case Report
CRP Flare Response and Response to Nivolumab in Kidney Cancer
Stereotactic Body Radiotherapy for Metastatic Kidney Cancer: U.S. Temporal Trends
FDA Grants Priority Review to Pembrolizumab/Lenvatinib Combination for Kidney Cancer
Chemerin Overexpression in Clear Cell Kidney Cancer: Lipid Metabolism and Tumorigenesis
Is Plasma KIM-1 Linked to Recurrence Risk After Nephrectomy?
CheckMate 9ER: Cabozantinib Plus Nivolumab Versus Sunitinib in Kidney Cancer
Asymptomatic CNS Involvement From Advanced Renal Cell Carcinoma
AACR 2021: Overall Survival Update From IMmotion151 in Advanced Kidney Cancer
AACR 2021: Combination Targeted Therapies Under Study in Resistant Kidney Cancer
Do Proton Pump Inhibitors Influence Cabozantinib Outcomes in Metastatic Kidney Cancer?
Two Perspectives on One Woman’s Successful Robotic Kidney-Sparing Surgery
Prognostic Role of Sarcopenia for Targeted Therapy in Metastatic Kidney Cancer
IGLL5 Expression in Clear Cell Kidney Cancer: Potential Prognostic Biomarker?
Tivozanib Versus Sorafenib in Refractory Renal Cell Carcinoma
CLEAR Trial: Targeted Therapy Plus Immunotherapy in Advanced Renal Cell Carcinoma
Plasma KIM-1: Biomarker for Recurrence Risk After Surgery for Localized Kidney Cancer?
Advanced Renal Cell Carcinoma: Focus on Gender and Racial Differences in Treatment
FDA Grants Priority Review to HIF-2α Inhibitor for Renal Cell Carcinoma
Comparing Immunotherapy Regimens in Metastatic Kidney Cancer
FDA Approval Granted to Tivozanib for Advanced Renal Cell Carcinoma
GU Symposium 2021: Radiotherapy Plus Pembrolizumab for Oligometastatic Kidney Cancer
GU Symposium 2021: Novel mTOR1/2 Inhibitor Under Study in Metastatic Kidney Cancer
Nivolumab as Neoadjuvant Therapy in High-Risk Clear Cell Renal Cell Carcinoma
GU Symposium 2021: Updated CheckMate 9ER Results on Nivolumab Plus Cabozantinib in Kidney Cancer
Does Metastatic Tumor Shrinkage Influence Overall Survival in Renal Cell Carcinoma?
GU Symposium 2021: Cabozantinib Emerges From SWOG 1500 Trial of Metastatic Papillary Kidney Cancer
GU Symposium 2021: CLEAR Trial of Lenvatinib and Pembrolizumab or Everolimus in Kidney Cancer
Impact of the Affordable Care Act in Renal Cell Carcinoma
GU Symposium 2021: Oral HIF-2α Inhibitor Plus Cabozantinib in Advanced Kidney Cancer
GU Symposium 2021: Cabozantinib for Renal Cell Carcinoma With Brain Metastases
After Cytoreductive Nephrectomy: When Is More Treatment of Benefit?
Venous Thromboembolism at the Time of Surgery for a Renal Mass: Clinical Implications
Novel HIF-2α Inhibitor Under Study in Von Hippel-Lindau–Associated Kidney Cancer


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.